These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31092693)

  • 1. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
    Kaplan AR; Gueble SE; Liu Y; Oeck S; Kim H; Yun Z; Glazer PM
    Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.
    Hegan DC; Lu Y; Stachelek GC; Crosby ME; Bindra RS; Glazer PM
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2201-6. PubMed ID: 20133863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
    PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of Cediranib-Olaparib Combo Revealed.
    Cancer Discov; 2019 Aug; 9(8):990-991. PubMed ID: 31182430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia.
    Bindra RS; Glazer PM
    Oncogene; 2007 Mar; 26(14):2048-57. PubMed ID: 17001309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NELF complex fosters BRCA1 and RAD51 recruitment to DNA damage sites and modulates sensitivity to PARP inhibition.
    Bishara LA; Machour FE; Awwad SW; Ayoub N
    DNA Repair (Amst); 2021 Jan; 97():103025. PubMed ID: 33248388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 10. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.
    Tao L; Zhou Y; Pan X; Luo Y; Qiu J; Zhou X; Chen Z; Li Y; Xu L; Zhou Y; Zuo Z; Liu C; Wang L; Liu X; Tian X; Su N; Yang Z; Zhang Y; Gou K; Sang N; Liu H; Zou J; Xiao Y; Zhong X; Xu J; Yang X; Xiao K; Liu Y; Yang S; Peng Y; Han J; Cen X; Zhao Y
    Nat Commun; 2023 Nov; 14(1):7430. PubMed ID: 37973845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
    Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R
    J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
    Tacconi EM; Lai X; Folio C; Porru M; Zonderland G; Badie S; Michl J; Sechi I; Rogier M; Matía García V; Batra AS; Rueda OM; Bouwman P; Jonkers J; Ryan A; Reina-San-Martin B; Hui J; Tang N; Bruna A; Biroccio A; Tarsounas M
    EMBO Mol Med; 2017 Oct; 9(10):1398-1414. PubMed ID: 28729482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair.
    Altwerger G; Ghazarian M; Glazer PM
    Semin Cancer Biol; 2024 Jan; 98():11-18. PubMed ID: 38029867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
    Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
    J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGFβ induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
    Liu L; Zhou W; Cheng CT; Ren X; Somlo G; Fong MY; Chin AR; Li H; Yu Y; Xu Y; O'Connor ST; O'Connor TR; Ann DK; Stark JM; Wang SE
    Mol Cancer Res; 2014 Nov; 12(11):1597-609. PubMed ID: 25103497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.